Avapritinib (BLU-285)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Avapritinib (BLU-285), covering 2025-09-23 to 2025-09-23. Get the full timeline:
Most recent: Clinical Trial Update: (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis [Phase 2]